Understanding Bowel Function and Quality of Life After Right-Sided Colon Cancer Surgery: What Patients Should Know

Table of Contents

• Key Points
• Why This Research Matters
• How the Study Was Conducted
• Key Findings: Quality of Life After Surgery
• Key Findings: Bowel Function After Surgery
• Key Findings: Medication Use for Bowel Symptoms
• Factors That Influence Bowel Function
• What This Means for Patients
• Study Limitations
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• In a study of 57 patients, most bowel symptoms and quality-of-life measures improved significantly over 18 months after minimally invasive right-sided colectomy with D3 lymphadenectomy.
• By 18 months, 96% of patients had no bowel dysfunction, compared with 77% before surgery, but urgency did not significantly improve and remained a common complaint.
• About 10% of patients consistently needed medication for bowel symptoms throughout the 18-month follow-up, including antidiarrheal agents, bulking agents, and stool softeners.
• Chemotherapy after surgery was linked to worse insomnia and total symptom scores, but this effect was temporary and typically improved after treatment ended.
• Longer bowel resection was associated with bowel dysfunction at 6 months, but this did not hold in multivariate analysis, suggesting the body adapts over time.

Why This Research Matters

As the number of people diagnosed with colorectal cancer continues to rise, the challenges faced by cancer survivors after treatment have become an increasingly important issue. In many cases, patients experience changes in bowel habits, urination problems, and sexual dysfunction after surgery—but these functional issues are often overlooked in favor of focusing on short-term surgical complications and long-term cancer outcomes.

Many patients report a poor quality of life (QOL) because of these functional problems. Previous research has shown that dysfunction after rectal resection or left-sided colectomy (surgery on the left side of the colon) is particularly severe. Low anterior resection syndrome (LARS) is a term used to describe bowel habit changes that occur after rectal surgery, including symptoms such as urgency, frequent bowel movements, stool fragmentation, fecal incontinence (leaking stool), difficulty emptying the bowels, and increased gas. LARS is generally caused by a combination of problems, including abnormal colonic motility (movement of the digestive tract), reduced function of the new rectum reservoir, and damage to the anal sphincter or pelvic nerves—though the severity of symptoms varies greatly from patient to patient.

Compared with the bowel changes seen after rectal or left-sided colon surgery, bowel dysfunction after right-sided colectomy has traditionally been considered relatively mild and temporary. Because the proximal colon (first part of the colon) and the terminal ileum (end of the small intestine) are mainly responsible for absorbing water, patients may experience temporary diarrhea after surgery. Over time, the small bowel adapts and absorbs more water, so diarrhea usually improves.

However, some patients experience very severe, persistent bowel symptoms that do not get better even with medication. Since the concept of complete mesocolic excision (CME)—a more extensive surgical removal of tissue around the colon—was introduced, the scope of right-sided colectomy has become more extensive. This raises concerns that the risk of bowel dysfunction due to damage to the superior mesenteric nerve plexus (a network of nerves supplying the intestine) has increased. Despite these concerns, very few studies have examined bowel dysfunction after right-sided colectomy. This study was designed to fill that gap by tracking changes in bowel function and quality of life over time.

How the Study Was Conducted

Researchers at Korea University ANAM Hospital in Seoul, South Korea, included patients who underwent laparoscopic (minimally invasive) or robotic-assisted right hemicolectomy or extended right hemicolectomy for colon cancer between October 2017 and September 2018. Patients diagnosed with adenocarcinoma of the appendix, cecum, ascending colon, hepatic flexure, or proximal transverse colon were included, and patients of all disease stages were eligible. Patients who did not complete the questionnaires were excluded from the study.

The study was approved by the Institutional Review Board of Korea University ANAM Hospital (IRB No. 2020AN0004), and all participants provided informed consent. The hospital follows a standard recovery pathway: a soft diet is allowed on the second day after surgery if there are no complications, and antidiarrheal or constipation medications are prescribed as needed based on symptoms.

All patients underwent right hemicolectomy or extended right hemicolectomy with D3 lymph node dissection. In this procedure, the bowel is removed from the terminal ileum to the transverse colon, and the ileocolic and right colic arteries are divided at their origin from the superior mesenteric artery. The surgery also divides the right branch or the root of the middle colic artery, which is part of the D3 lymphadenectomy approach.

Patients who had stage 2 disease with risk factors or stage 3 disease received oxaliplatin-based adjuvant chemotherapy (the FOLFOX4 regimen) for 8 to 12 cycles, or 5-fluorouracil with leucovorin (the FL regimen) for 6 cycles after surgery.

Questionnaires about quality of life and bowel symptoms were collected prospectively (planned in advance) at five time points: before surgery, and then at 3, 6, 12, and 18 months after the operation. The quality-of-life assessment used version 3 of the European Organization for Research and Treatment of Cancer (EORTC) Core QOL Questionnaire (QLQ-C30), a widely validated tool. Bowel function was evaluated based on five specific symptoms: gas, stool leakage, frequency, fragmentation (incomplete emptying or passing stool in pieces), and urgency.

Patients were classified into groups based on their bowel dysfunction scores:

• No bowel dysfunction: scores of 0–20 points
• Minor dysfunction: scores of 21–29 points
• Major dysfunction: scores of 30–42 points

Statistical analysis was performed using the Statistical Package for the Social Sciences version 20.0 (IBM Corp., Armonk, NY, United States). Changes in quality-of-life and bowel dysfunction scales were analyzed using the Wilcoxon single-rank test, comparing follow-up scores to preoperative baseline scores. Correlations between factors were analyzed using linear regression, and risk factors for bowel dysfunction were identified using Cox regression analysis. P values less than 0.05 were accepted as statistically significant.

Key Findings: Quality of Life After Surgery

A total of 336 patients participated in the broader questionnaire program during the study period. Of these, 57 patients underwent right or extended right hemicolectomy with a minimally invasive approach and were included in this analysis. The number of patients who completed questionnaires decreased over time: 47 patients responded at 3 months, 52 at 6 months, 52 at 12 months, and 25 at 18 months after surgery.

Who Were the Patients?

The average patient age was 63.8 years (range: 36–80 years). The group included 30 men (52.6%) and 27 women (47.4%), with an average body mass index (BMI) of 23.7 kg/m² (range: 18.6–33.9). Most patients had tumors in the ascending colon (33 patients, 57.9%), followed by the cecum (9 patients, 15.8%), hepatic flexure (7 patients, 12.3%), transverse colon (5 patients, 8.8%), and appendix (3 patients, 5.3%).

The majority of surgeries were laparoscopic (56 patients, 98.2%), with just one robotic-assisted surgery (1.8%). Most patients underwent right hemicolectomy (47 patients, 82.5%), while 10 patients (17.5%) had extended right hemicolectomy. The average resected bowel length was 36.3 cm (range: 19.0–69.5 cm), including an average colon length of 26.7 cm (range: 9.5–56.0 cm) and ileum length of 9.9 cm (range: 3.2–35.5 cm). Ten patients (17.5%) had preoperative bowel obstruction.

Regarding cancer stages, 8 patients (14.0%) had stage 0 disease, 11 (19.3%) had stage 1, 19 (33.3%) had stage 2, 14 (24.6%) had stage 3, and 5 (8.8%) had stage 4. No patients received chemotherapy before surgery, and 18 patients (31.6%) received chemotherapy after surgery.

Quality of Life Results

Most quality-of-life scales improved significantly over the 18-month follow-up period. Global health status (overall well-being) rose from 59.5 before surgery to 74.0 at 18 months—a substantial improvement (P = 0.001).

Functional scales also showed strong gains:

• Role functioning (ability to perform daily activities): improved from 86.8 to 98.7 (P = 0.001)
• Emotional functioning (mental well-being): improved from 81.9 to 99.3 (P < 0.001)
• Social functioning (ability to maintain social roles): improved from 81.6 to 97.3 (P < 0.001)
• Physical functioning: remained stable (87.4 to 88.3, P = 0.530)
• Cognitive functioning: showed no significant change (91.2 to 94.0, P = 0.104)

Symptom scores (where lower is better) also improved significantly for most measures:

• Fatigue: decreased from 22.4 to 12.0 (P = 0.001)
• Nausea and vomiting: decreased from 8.8 to 0.0 (P = 0.001)
• Pain: decreased from 17.8 to 2.0 (P < 0.001)
• Dyspnea (shortness of breath): decreased from 9.9 to 1.3 (P = 0.021)
• Insomnia: decreased from 14.6 to 4.0 (P = 0.009)
• Appetite loss: decreased from 18.7 to 1.3 (P < 0.001)
• Constipation: decreased from 18.1 to 5.3 (P = 0.006)
• Diarrhea: decreased from 15.8 to 5.3 (P = 0.010)
• Financial difficulties: decreased from 21.1 to 9.3 (P < 0.001)

The total symptom score dropped dramatically from 147.3 before surgery to 40.7 at 18 months (P < 0.001). Notably, patients reported a high burden of fatigue and financial difficulties throughout the study period—a finding that highlights the real-world challenges cancer patients face beyond their physical symptoms.

Interestingly, many symptom scores showed a temporary worsening at 6 months, followed by improvement at 12 months, and then some symptoms worsened again by 18 months. This pattern may reflect the effects of chemotherapy, which was most common during the early post-surgical period.

Impact of Chemotherapy on Quality of Life

At 3 and 6 months after surgery, about 35–40% of patients were receiving chemotherapy (38.3% of responders at 3 months and 34.6% at 6 months received FOLFOX; 2.1% and 1.9% respectively received FL). By 12 months, only 1 patient (1.9%) was still on FOLFOX.

Chemotherapy had a measurable impact on quality of life. Patients receiving chemotherapy had significantly worse insomnia scores (P = 0.005) and total symptom scores (P = 0.017). However, there was no difference in results based on which chemotherapy regimen (FOLFOX vs. FL) patients received.

Key Findings: Bowel Function After Surgery

Most bowel function measures improved significantly over time, but not all of them. The bowel symptom scores (where lower is better) showed the following changes from before surgery to 18 months after:

• Gas: decreased from 3.6 to 0.8 (P < 0.001)—a significant improvement
• Stool leakage: decreased from 0.4 to 0.0 (P = 0.025)—leakage was very rare throughout the entire study
• Frequency (number of bowel movements): decreased from 1.7 to 0.5 (P = 0.014)
• Fragmentation (stool passing in pieces): decreased from 2.9 to 1.2 (P = 0.037)
• Urgency (urgent need to have a bowel movement): decreased from 3.8 to 2.0, but this change was NOT statistically significant (P = 0.217)
• Total bowel score: decreased from 12.4 to 4.5 (P < 0.001)

The fact that urgency persisted throughout the study period without significant improvement is an important finding. While most bowel symptoms gradually resolved, urgency remained a consistent complaint—and it was associated with worse quality of life across most functional and symptom scores. This matches other research: Bertelsen and colleagues reported urgency rates of 35.3% to 37.4% in patients who underwent right-sided colectomy, though their study did not track how the severity changed over time.

Patients were also classified into bowel dysfunction groups based on their scores. Before surgery, 44 patients (77.2%) had no bowel dysfunction, 5 (8.8%) had minor dysfunction, and 8 (14.0%) had major dysfunction. By 18 months after surgery, 24 patients (96.0%) had no dysfunction, 1 (4.0%) had minor dysfunction, and none had major dysfunction. This shift was statistically significant (P = 0.014), showing that most patients' bowel function normalized or improved after surgery.

Key Findings: Medication Use for Bowel Symptoms

Throughout the entire study period, approximately 10% of patients consistently needed medication to manage their bowel function. The specific numbers were:

• Before surgery: 5 patients (8.8%) were taking bowel medications
• At 3 months: 6 patients (12.8%)
• At 6 months: 6 patients (11.5%)
• At 12 months: 5 patients (9.6%)
• At 18 months: 2 patients (8.0%)

The rate of medication use did not change significantly over time (P = 0.882). The types of medications used included antidiarrheal agents, bulking agents, and stool softeners. For example, stool softeners were used by 3 patients (5.3%) before surgery, by 4 patients (8.5%) at 3 months, by 4 patients (7.7%) at 6 months, by 1 patient (1.9%) at 12 months, and by 2 patients (8.0%) at 18 months.

The consistent ~10% medication rate is noteworthy. Even though most patients recovered well, a stable subset of patients continued to struggle with bowel symptoms long after surgery. The correlation analysis showed that patients taking medication had significantly more gas (P = 0.023) and more frequent bowel movements (P < 0.001), and were significantly more likely to be in the bowel dysfunction group (P = 0.028).

Factors That Influence Bowel Function

The researchers performed detailed statistical analyses to identify which patient and surgical factors were associated with bowel symptoms. Several significant associations emerged:

• Gas was associated with resected colon length (P = 0.032) and disease stage (P = 0.013)
• Leakage was related to body mass index (P = 0.005) and colon length (P = 0.011)
• Frequency of bowel movements was related to sex (P = 0.002)
• Overall bowel score was related to disease stage (P = 0.020)

Additionally, the quality-of-life analysis revealed that most bowel symptoms—except leakage—adversely affected most functional and symptom quality-of-life scales. Emotional and social functioning were particularly strongly associated with bowel symptoms, meaning that patients with worse bowel symptoms also tended to have worse emotional well-being and social participation.

When comparing patients in the bowel dysfunction group (minor and major combined) to those with no dysfunction at 6 months after surgery, univariate analysis showed that the total resected bowel length (odds ratio [OR]: 1.095, P = 0.026) and colon length (OR: 1.147, P = 0.031) were significantly different between the two groups. This means that for each additional centimeter of bowel removed, the risk of being in the dysfunction group increased by approximately 9.5%, and for each additional centimeter of colon removed, the risk increased by about 14.7%. However, this finding did not hold up in multivariate analysis, which means that when other factors were accounted for simultaneously, the length of bowel removed was no longer a statistically significant independent predictor of bowel dysfunction.

Interestingly, these length-related differences were only significant at the 6-month time point—not at other follow-up visits. This suggests that the length of bowel removed may have a temporary effect on bowel function during the early recovery period, but that the body adapts over time.

What This Means for Patients

This study provides reassuring evidence that most patients undergoing right-sided colectomy with D3 lymphadenectomy using a minimally invasive approach can expect their bowel function and quality of life to improve significantly over time. By 18 months after surgery, nearly all patients (96%) had no bowel dysfunction at all—even better than before their surgery, when 77.2% had no dysfunction.

The findings are particularly meaningful because they address concerns about complete mesocolic excision (CME). In Western countries, where CME has only recently been adopted, there has been concern that the more extensive surgery—which involves cutting the superior mesenteric nerve plexus—could cause small bowel denervation (loss of nerve supply) and increase bowel frequency. However, in Eastern countries like South Korea and Japan, D3 lymphadenectomy has been performed routinely for years, and bowel dysfunction has not been a major clinical issue. This study supports those experiences, as does research by Bertelsen and colleagues, who found that CME did not increase the degree of bowel dysfunction compared with conventional surgery.

However, the study also highlights one persistent problem: urgency. Unlike other bowel symptoms that improved, urgency remained high throughout the study period and was linked to worse quality of life across many measures. This is consistent with prior research showing that urgency is a common complaint even after right-sided colectomy, affecting more than one-third of patients in some studies.

The finding that approximately 10% of patients consistently need medication for bowel symptoms is also clinically important. These are patients who do not fully recover their bowel function and may require ongoing support. Since bowel function was significantly correlated with emotional and social quality of life, actively managing bowel symptoms—through medication, dietary adjustments, or other strategies—may meaningfully improve these patients' overall well-being.

Study Limitations

It's important to interpret these findings in the context of the study's limitations. First, the sample size was relatively small—57 patients total, with only 25 (44%) remaining at the 18-month follow-up point. This attrition rate means that the 18-month data should be interpreted with some caution, as the patients who dropped out may have had different outcomes than those who remained.

Second, this was a single-institution study from one hospital in South Korea. The results may not be fully generalizable to other hospitals or countries with different patient populations, surgical techniques, or postoperative care protocols.

Third, while the data were collected prospectively (forward-looking), the analysis itself was retrospective (looking back at collected data), which carries inherent limitations in establishing cause-and-effect relationships.

Fourth, the study did not include a comparison group of patients who underwent conventional (non-D3) surgery, so it cannot directly prove that D3 lymphadenectomy is equivalent to less extensive surgery in terms of functional outcomes—though the comparison with historical data from other studies is reassuring.

Fifth, urination and sexual function—two other important quality-of-life domains—were not assessed in patients who received right-sided colectomy. This means the study cannot comment on how the surgery affects these functions.

Finally, the risk factor analysis for bowel dysfunction identified associations (such as bowel length), but these were not confirmed in multivariate analyses, and the small sample size limits the statistical power to detect true risk factors.

Recommendations for Patients

Based on the findings of this study, here are key takeaways for patients facing right-sided colon cancer surgery:

1. Expect improvement over time. Most bowel symptoms and quality-of-life measures improve significantly in the months after surgery. The first few months may be challenging, especially with chemotherapy, but most patients see substantial gains by 6–12 months.
2. Be aware that urgency may persist. Unlike other symptoms, the urgent need to have a bowel movement may not resolve on its own. If you experience persistent urgency, discuss it openly with your healthcare team—it can be treated, and managing it can significantly improve your quality of life.
3. Don't be afraid to use medication if needed. About 1 in 10 patients needs ongoing medication for bowel function after surgery. Taking antidiarrheal agents, bulking agents, or stool softeners is normal and acceptable—these medications exist to help you live comfortably.
4. Monitor emotional and social well-being. The study found that bowel symptoms are closely linked to emotional and social functioning. If you're feeling anxious, depressed, or socially isolated because of bowel symptoms, seek support. Your surgical team, a nutritionist, or a mental health professional can help.
5. Understand that chemotherapy may temporarily worsen symptoms. If you're receiving chemotherapy (like the FOLFOX or FL regimens used in this study), expect that some quality-of-life measures—particularly sleep and overall symptoms—may be worse during treatment. This is temporary and typically improves after chemotherapy ends.
6. Know that a longer bowel resection may mean a slower recovery. While the length of bowel removed wasn't an independent risk factor in this study, it was associated with bowel dysfunction at 6 months. If you had a longer resection, give your body time to adapt—the small bowel can compensate over time.
7. Keep following up. The study tracked patients for 18 months, and continued improvement was seen throughout that period. Stay engaged with your follow-up care, and report any persistent bowel symptoms to your doctor rather than suffering in silence.

This research adds to the growing evidence that right-sided colectomy with D3 lymphadenectomy—even with the more extensive tissue removal involved—does not condemn most patients to permanent bowel dysfunction. With appropriate medical support, the vast majority of patients recover good bowel function and quality of life after surgery.

Frequently Asked Questions

What is a right-sided colectomy with D3 lymphadenectomy?

It is surgery to remove the right side of the colon, from the end of the small intestine to the transverse colon, along with extensive lymph node removal. In the 57 patients studied, the procedure was done using a minimally invasive (laparoscopic or robotic) approach. The average length of bowel removed was about 36 cm.

Will my bowel function improve after right-sided colectomy?

In a study of 57 patients, most bowel symptoms improved significantly over 18 months. By 18 months, 96% had no bowel dysfunction, compared with 77% before surgery. Gas, stool leakage, frequency, and fragmentation all decreased. However, urgency (the sudden need to go) did not significantly improve and remained a common complaint.

What is urgency and why does it matter after surgery?

Urgency is a sudden, strong need to have a bowel movement. In the 57 patients studied, urgency scores did not improve significantly over 18 months, unlike other bowel symptoms. Persistent urgency was linked to worse quality of life across many measures. If you have ongoing urgency, discuss it with your healthcare team, as it can be managed.

What factors influence bowel function after right-sided colectomy?

In the 57 patients studied, gas was associated with resected colon length and disease stage; leakage with body mass index and colon length; and frequency with sex. At 6 months, each additional centimeter of bowel removed was linked to a higher chance of bowel dysfunction, but this did not hold in multivariate analysis, suggesting a temporary effect.

When should a patient with right-sided colon cancer considering minimally invasive colectomy with D3 lymphadenectomy seek a second opinion?

A second opinion is worth considering before surgery to confirm the diagnosis and review whether the planned right hemicolectomy or extended right hemicolectomy with D3 lymph node dissection is appropriate. Bowel function and quality of life generally improve over 18 months, but urgency often persists and about 10% of patients need ongoing bowel medication, so reviewing the extent of resection and expected functional outcomes with another specialist can help. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Bowel function and quality of life after minimally invasive colectomy with D3 lymphadenectomy for right-sided colon adenocarcinoma

Authors: Ki-Myung Lee, Se-Jin Baek, Jung-Myun Kwak, Jin Kim, Seon-Hahn Kim

Affiliation: Department of Surgery, Korea University College of Medicine, Seoul, South Korea

Journal: World Journal of Gastroenterology, September 7, 2020; Volume 26, Issue 33; Pages 4972–4982

DOI: 10.3748/wjg.v26.i33.4972

Study approval: Institutional Review Board of Korea University ANAM Hospital, IRB No. 2020AN0004

Note: This patient-friendly article is based on peer-reviewed research published in the World Journal of Gastroenterology. It is intended for educational purposes and is not a substitute for professional medical advice. Patients should always consult their healthcare providers about their individual treatment and recovery plans.